Nonviral Gene Delivery: Principle, Limitations, and Recent Progress

被引:514
作者
Al-Dosari, Mohammed S. [1 ]
Gao, Xiang [2 ]
机构
[1] King Saud Univ, Coll Pharm, Dept Pharmacognosy, Riyadh 11451, Saudi Arabia
[2] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA
关键词
gene delivery; gene therapy; lipoplex; nonviral vectors; polyplex; transfection; TERM TRANSGENE EXPRESSION; MEDIATED DNA-TRANSFECTION; LOW-MOLECULAR-WEIGHT; IN-VIVO; PLASMID DNA; JET-INJECTION; HIGHLY EFFICIENT; VECTORS; LIVER; CELLS;
D O I
10.1208/s12248-009-9143-y
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Gene therapy is becoming a promising therapeutic modality for the treatment of genetic and acquired disorders. Nonviral approaches as alternative gene transfer vehicles to the popular viral vectors have received significant attention because of their favorable properties, including lack of immunogenicity, low toxicity, and potential for tissue specificity. Such approaches have been tested in preclinical studies and human clinical trials over the last decade. Although therapeutic benefit has been demonstrated in animal models, gene delivery efficiency of the nonviral approaches remains to be a key obstacle for clinical applications. This review focuses on existing and emerging concepts of chemical and physical methods for delivery of therapeutic nucleic acid molecules in vivo. The emphasis is placed on discussion about problems associated with current nonviral methods and recent efforts toward refinement of nonviral approaches.
引用
收藏
页码:671 / 681
页数:11
相关论文
共 101 条
[1]
Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis [J].
Akinc, A ;
Thomas, M ;
Klibanov, AM ;
Langer, R .
JOURNAL OF GENE MEDICINE, 2005, 7 (05) :657-663
[2]
Activation of human CYP2C9 promoter and regulation by CAR and PXR in mouse liver [J].
Al-Dosari, Mohammed S. ;
Knapp, Joseph E. ;
Liu, Dexi .
MOLECULAR PHARMACEUTICS, 2006, 3 (03) :322-328
[3]
Hydrodynamic Delivery [J].
Al-Dosari, Mohammed S. ;
Knapp, Joseph E. ;
Liu, Dexi .
NON-VIRAL VECTORS FOR GENE THERAPY, SECOND EDITION: PART 2, 2005, 54 :65-82
[4]
DNA electrotransfer:: its principles and an updated review of its therapeutic applications [J].
André, F ;
Mir, LM .
GENE THERAPY, 2004, 11 (Suppl 1) :S33-S42
[5]
Persistent episomal transgene expression in liver following delivery of a scaffold/matrix attachment region containing non-viral vector [J].
Argyros, O. ;
Wong, S. P. ;
Niceta, M. ;
Waddington, S. N. ;
Howe, S. J. ;
Coutelle, C. ;
Miller, A. D. ;
Harbottle, R. P. .
GENE THERAPY, 2008, 15 (24) :1593-1605
[6]
Physical factors affecting kinesin-based transport of synthetic nanoparticle cargo [J].
Bachand, M ;
Trent, AM ;
Bunker, BC ;
Bachand, GD .
JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY, 2005, 5 (05) :718-722
[7]
Lipoplex-mediated gene delivery to the lung occurs within 60 minutes of intravenous administration [J].
Barron, LG ;
Gagné, L ;
Szoka, FC .
HUMAN GENE THERAPY, 1999, 10 (10) :1683-1694
[8]
Bastos R, 1995, INT REV CYTOL, V162B, P257
[9]
Use of ultrasound contrast agents for gene or drug delivery in cardiovascular medicine [J].
Bekeredjian, R ;
Grayburn, PA ;
Shohet, RV .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (03) :329-335
[10]
LIPOSOMES FOR THE SUSTAINED DRUG RELEASE INVIVO [J].
BLUME, G ;
CEVC, G .
BIOCHIMICA ET BIOPHYSICA ACTA, 1990, 1029 (01) :91-97